Concurrent modulation of 5-fluorouracil with methotrexate and L- leucovorin: An effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma a multicenter phase II study of the southern Italy cooperative oncology group

Tumori

Volumn 85, Issue 6, 1999, Pages 465-472

  Comella, Pasquale ^a   Lorusso, Vito ^b   Casaretti, Rossana ^a   De Lucia, Luigi ^c   Cartenì, Giacomo ^d   Manzione, Luigi ^e   Mancarella, Sergio ^b   De Lena, Mario ^b   Comella, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c City Hospital   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e Medical Oncology Unit   (Italy)

Author keywords

5FU modulation; Colorectal carcinoma; MTX + 5FU + LV regimen

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONJUNCTIVITIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HAIR LOSS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; TREATMENT INDICATION;

EID: 0033370189     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500608     Document Type: Article

References (35)

1. Abad A., Garcia P., Gravalos C., Tusquets I., Font A., Perez G., Cortés-Funes H., Fabregat X., Barnadas A., Resell R.: Sequential methotrexate, 5-fluorouracil (5FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer, 75: 1238-1244, 1995.
2. Abad A., Rosell R., Pastor M.C., Barnadas A., Carles J., Ribelles N., Oiler B., Armengol M., Salva A., Ribas M. Sequential combination of methotrexate (MTX), 5-fluorouracil (FU) and high-dose folinic acid (FA) in advanced colorectal cancer: Double biochemical modulation? Am. J. Clin. Oncol., 14:393-396, 1991.
3. Aranda E., Cervantes A., Carrato A., Fernández-Martos C., Antón-Torres A., Massuttí T., Barneto I., García-Conde J., Baron J.M., Díaz-Rubio E.: Outpatient weekly high dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Ann. Oncol., 7: 581-585, 1996.
4. Beerblock K., Rinaldi Y., André T., Louvet C., Raymond E., Tournigand C., Carola E., Favre R., de Gramont A., Krulik M.: Bimonthly high dose leuvocorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Cancer, 79: 1100-1115, 1997.
5. Bertheault-Cvitkovic F., Jami A., Ithzaki M., Deprés Brummer P., Brienza S., Adam R., Kunstlinger F., Bismuth H., Misset J.L., Lévi F.: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 2950-2958, 1996.
6. Blanke C.D., Kasimis B., Schein P., Capizzi R., Kurman M.: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J. Clin. Oncol., 15: 915-920, 1997.
7. Buroker T.R., O'Connell M.J., Wieand H.S., Krook J.E., Gerstner J.B., Mailliard J.A., Schaefer P.L., Levitt R., Kardinal C.G., Gesme D.H.: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol., 12: 14-20, 1994.
8. Colucci G., Maiello E., Leo S., Giuliani F., Pedicini A., Pezzella G., Valori V., Galetta D., Contillo A., Prete F.: Biochemical modulation of fluorouacil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Anticancer Res., 14: 2157-62, 1994.
9. Comella P., Palmieri G., Beneduce G., Casaretti R., Daponte A., Gravina A., Frasci G., Biondi E., Comella G.: Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, 1-folinic acid and 5-fluorouracil. Oncology, 53: 198-203, 1996.
10. Comella P., Palmieri G., Lorusso V., Catalano G., Nicolella D., Ianniello G.P., Casaretti R., Montella M., Frasci G., Perna M., Comella G.: Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur. J. Cancer, 32A: 1719-1726, 1996.
11. Conti J.A., Kemeny N., Seiter K., Goker E., Tong W., McKenzie A., Ragusa K., Bertino J.R.: Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J. Clin. Oncol., 12: 695-700, 1994.
12. de Gramont A., Bosset J-F., Milan C., Rougier P., Bouché O., Etienne P-L., Marvan F., Louvet C., Guillot T., François E., Bedenne L.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J. Clin. Oncol., 15: 808-815, 1997.
13. Dixon W.J., BMDP Statistical Software. University of California Press, Berkely, CA, 1988.
14. Garufi C., Lévi F., Aschelter A.M., Pace R., Giunta S., Nisticò C., Gallà D.A.P., Silecchia G.F., Franchi F., Narduzzi C., Terzoli E.: A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. Eur. J. Cancer, 33: 1566-1571, 1997.
15. Glimelius B. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann. Oncol., 4: 235-250, 1993.
16. Hryniuk W.H., Goodyear M.: The calculation of received dose intensity. J. Clin. Oncol, 8: 1935-1937, 1995.
17. Jäger E., Heike M., Bernhard H., Klein O., Bernhard G., Lautz D.: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. J. Clin. Oncol., 14: 2274-2279, 1996.
18. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
19. Labianca R., Cascinu S., Frontini L., Barni S., Fiorentini G., Comella G., Zaniboni A., Gottardi O., Arnoldi E., Oliani C., Duro M., Pavanato G., Martignoni G., Raina A., Piazza E., Dallavalle G., Valsecchi R., Pancera G., Luporini G.: High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. Ann. Oncol., 8: 169-74, 1997.
20. Lokich J.J., Ahlgren J.D., Gullo J.J., Philips J.A., Fryer J.G.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J. Clin. Oncol., 7: 425-432, 1989.
21. Miller A.B., Hoogstraten B., Staquet M., Winkler V.: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
22. Mortel C.G.: Chemotherapy of gastrointestinal cancer. NE-JM, 299: 1049-1052, 1978.
23. Peto R., Pike M.C., Armitage P.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 35: 1-39, 1977.
24. Petrelli N., Herrera L., Rustum Y., Burke P., Creaven P., Stulc J., Emrich L.J., Mittelman A.: A prospective randomized trial of 5-fluorouracil versus 5-flurouracil and high-dose leucovorin versus 5-flurouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol., 5: 1559-1565, 1987.
25. Polyzos A., Tsavaris N., Giannopoulos C., Bacoyiannis C., Papadimas V., Kalahanis N., Karatzas G., Kosmas C., Sakelaropoulos N., Archimandritis A., Papachristodoulou A., Kosmidis P.: Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Cancer Chemother. Pharmacol., 38: 292-297, 1996.
26. Poon M.A., O'Connell M.J., Wieand H.S., Krook J.E., Gerstner J.B., Tschetter L.K., Wiensenfeld M.: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
27. Richards F., Capizzi R.L., Muss H., Cruz J., Powell B., White D., Jackson D., Atkins A., Caldwell L., Puckett J., Christian E., Schnell F., Sharpe S., Stanley V., Brockschmidt J.: 5-Fluorouracil (5-FU), high dose folinic acid (FA) and methotrexate (MTX) for advanced colorectal cancer: A phase II trial of the Piedmont Oncology Association (Abst.). Proc. Am. Soc. Clin. Oncol., 8: 101, 1989.
28. Ross P.J., Webb A., Cunningham D., Prendiville J., Norman A.R., Oates J.: Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience. Ann. Oncol., 8: 111-115, 1997.
29. Rougier Ph., Paillot B., LaPlanche A., Morvan F., Seitz J.F., Rekacewicz, C., Laplage P., Jacob J., Grandjouan S., Tigaud J.M., Fabri M.C., Luboinski M., Ducreux M.: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomized trial in metastatic colorectal cancer. Eur. J. Cancer. 33: 1789-1793, 1997.
30. Simon R.: Optimal two-stage designs for phase II clinical trials. Contr. Clin. Trials, 10: 1-10, 1989.
31. Sobrero A., Frassineti G.L., Giuliani R., Caroti C., Ravaioli A., Lanfranco C., Caprioni F, Alghisi A., Arnoldi E., Barni S., Gallo L., Pessi M.A., Guglielmi A., Turci D., Cortesi E., Milandri C., Aschele C., Grossi F, Labianca R.: Randomized comparison between sequential MTX→FU and schedule specific biochemical modulation in advanced colorectal cancer (ACRC). Ann. Oncol., 9 (Suppl. 4): 33, 1998.
32. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
33. The Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol., 12: 960-969, 1994.
34. Valone F.H., Friedman M.A., Wittlinger P.S., Drakes T., Eisenberg P.D., Malec M., Hannigan A. J.F., Brown B.W.: Treatment of patients with advanced colorectal carcinoma with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J. Clin. Oncol., 7: 1427-1436, 1989.
35. Van der Wilt C.L., Braakhuis B.J.M., Pinedo H.M., De Jong M., Smid K., Peters G.J.: Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int. J. Cancer. 61: 672-678, 1995.